Sox, I am guessing you will never admit you are wr
Post# of 72440
Secondly in Leo’s email response to BooDog “ACTUALLY THEY HAVE CONVERTED VERY FEW PREFERRED SHARES SO THE SELLING IS BY OTHERS. THEY SEEM TO BE EXPECTING HIGHER SHARE PRICES, but this is merely my speculation. “
I have agreed with you in the past (see post # 47155) that dilution was PARTLY responsible for the decrease in share price “I personally believe that Sox's position on Aspire selling is valid and is backed by historical facts and data. I also believe Allan & 4kids are correct that there is a significant NSS issue that is more difficult to quantify but it doesn't make it any less real. The longs on this board (retail) have not been able to win the share price war against the shorts and Aspire selling that has been necessary to fund expensive FDA trials.’
BUT if you look at Drano’s post #50566 he clearly lays out comparative pre-revenue biotech valuations that make our current $22M valuation a joke. If you need further proof please check out science and market based stickies above. Oh, that’s right you authored the top 3.
AND that brings us back to our many posters at the swamp. Some of the same cast of characters have been relentlessly bashing IPIX for several YEARS. There are only 2 logical conclusions for this. One is that they are shorts or part of a trading gang. The obvious question is why are they sticking around if they have been successful taking IPIX from almost $5 to 12 cents? I would think they would claim victory and move on to their next target. The second logical conclusion is that there is an entity that is funding the bashers to continue to cripple IPIX to either prevent or slow IPIX’s ability to bring their drugs to market. I have no idea what the motivation is but as the saying goes “follow the money” so I am hopeful at some point we will know the answer.
Pursuant to the Purchase Agreement, the undersigned irrevocably agrees with the Company that, from the date hereof until ninety (90) days following the first closing date of the Company’s offering of registered securities pursuant to an effective shelf registration statement on Form S-3 (File No. 333-220419) and the Purchase Agreement (the “Offering”) (such period, the “Restriction Period”), the undersigned will not offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the undersigned or any Affiliate (as defined in the Purchase Agreement) of the undersigned or any person in privity with the undersigned or any Affiliate of the undersigned), directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), with respect to, any shares of common stock of the Company or securities convertible, exchangeable or exercisable into, shares of common stock of the Company beneficially owned, held or hereafter acquired by the undersigned (the “Securities”)